"Shoulda, coulda, woulda" will probably be my investing epitaph. While there is no shortage of investment advice telling you that long-term investment success is predicated on developing a consistent method of evaluating stocks and sticking to your valuation guns, the consequences can be painful
A perfect case in point is Celldex Therapeutics (CLDX). I've always liked this development-stage biotech (and have written about it here and here...), but the price never seemed quite right to me. That "price discipline" has kept me on the sidelines as the stock has risen over 250% over the past year and 400% over the past two years, and the company has emerged as one of the most legitimate and...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: